drugset
Drugs / RTS,S/AS01E
last change Oct 2021 re-read 3 minutes ago

RTS,S/AS01E

also known as SB257049
Developed for
malaria
Investigated by
GlaxoSmithKline · PATH

Trials 1

today NCT03824236 · Ph 2
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03824236 Feb → Apr 2019 malaria GlaxoSmithKline Completed Met primary

Press releases naming this drug 2 releases

DateIssuerRelease
2021-10-06 GlaxoSmithKline GSK welcomes WHO recommendation for broad roll-out of its RTS,S/AS01e (RTS,S) malaria vaccine gsk.com ↗
2021-01-27 GlaxoSmithKline GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine gsk.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as RTS,S/AS01E ClinicalTrials.gov intervention name — accepted as the source's own label NCT03824236 ↗
Known as SB257049 “RTS,S/AS01E (SB257049)” NCT03824236 ↗